OCULAR THERAPEUTIX IN

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

14 11 2024 06:00:01 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

13 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

12 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

06 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

28 10 2024 09:00:04 提供 NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

21 10 2024 08:47:37 提供 NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

16 10 2024 14:33:40 提供 NetDania Notify

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

15 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

09 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

25 9 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 9 2024 15:05:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at September Retina Meetings

05 9 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Two Investor Conferences in September

04 9 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Second Quarter 2024 Results

07 8 2024 06:10:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

07 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

31 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

30 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 7 2024 15:05:00 提供 Nasdaq GlobeNewswire